-
公开(公告)号：US12049464B2
公开(公告)日：2024-07-30
申请号：US17901775
申请日：2022-09-01
发明人： Christopher G. Nasveschuk , Rhamy Zeid , Ning Yin , Katrina L. Jackson , Gesine Kerstin Veits , Moses Moustakim , Jeremy L. Yap
IPC分类号： C07D471/04 , A61P35/00 , C07D401/14
CPC分类号： C07D471/04 , A61P35/00 , C07D401/14
摘要： BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
-
公开(公告)号：US20230060334A1
公开(公告)日：2023-03-02
申请号：US17901775
申请日：2022-09-01
发明人： Christopher G. Nasveschuk , Rhamy Zeid , Ning Yin , Katrina L. Jackson , Gesine Kerstin Veits , Moses Moustakim , Jeremy L. Yap
IPC分类号： C07D471/04 , A61P35/00 , C07D401/14
摘要： BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
-
公开(公告)号：US20220372016A1
公开(公告)日：2022-11-24
申请号：US17351935
申请日：2021-06-18
发明人： Andrew J. Phillips , Christopher G. Nasveschuk , James A. Henderson , Katrina L. Jackson , Minsheng He , Yanke Liang , Mark E. Fitzgerald , Victoria Garza
IPC分类号： C07D401/14 , C07D401/04 , C07D401/10 , C07D239/22
摘要： This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.
-
公开(公告)号：US20210198256A1
公开(公告)日：2021-07-01
申请号：US17192634
申请日：2021-03-04
发明人： Christopher G. Nasveschuk , Ning Yin , Katrina L. Jackson , Gesine Kerstin Veits , Moses Moustakim , Jeremy L. Yap , Rhamy Zeid
IPC分类号： C07D471/04 , C07D401/14 , C07D417/14
摘要： Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.
-
公开(公告)号：US20240199581A1
公开(公告)日：2024-06-20
申请号：US18534395
申请日：2023-12-08
发明人： Christopher G. Nasveshuk , Katrina L. Jackson , Yanke Liang , Robert T. Yu , Martin Duplessis , Mark E. Fitzgerald , Victoria Garza , Andrew Charles Good , Morgan Welzel O'Shea , Gesine Kerstin Veits , Cosimo Dolente , David Stephen Hewings , Daniel Hunziker , Daniela Krummenacher , Piergiorgio Franceso Tommaso Pettazzoni , Juergen Wichmann
IPC分类号： C07D401/14 , A61P35/00 , C07D405/14 , C07D471/10 , C07D491/107 , C07D495/10
CPC分类号： C07D401/14 , A61P35/00 , C07D405/14 , C07D471/10 , C07D491/107 , C07D495/10
摘要： The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.
-
公开(公告)号：US20230372496A1
公开(公告)日：2023-11-23
申请号：US18134971
申请日：2023-04-14
发明人： Christopher G. Nasveschuk , Corey Don Anderson , James A. Henderson , Victoria Garza , Yanke Liang , Moses Moustakim , Katrina L. Jackson , Martin Duplessis
CPC分类号： A61K47/55 , A61K47/545
摘要： Heterobifunctional compounds for targeted protein degradation that include a tricyclic cereblon binder linked to an appropriate protein targeting ligand to degrade a targeted disease-mediating protein of interest are provided.
-
公开(公告)号：US20230145336A1
公开(公告)日：2023-05-11
申请号：US18084380
申请日：2022-12-19
发明人： Christopher G. Nasveschuk , Martin Duplessis , Mark E. Fitzgerald , Victoria Garza , Andrew Charles Good , Katrina L. Jackson , Yanke Liang , Moses Moustakim , Morgan Welzel O'Shea , Gesine Kerstin Veits , Jeremy L. Yap , Robert T. Yu , Cosimo Dolente , David Stephen Hewings , Daniel Hunziker , Bernd Kuhn , Piergiorgio Francesco Tommaso Pettazzoni , Fabienne Ricklin , Claus Riemer , Juergen Wichmann
IPC分类号： C07D471/04 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.
-
公开(公告)号：US20240245677A1
公开(公告)日：2024-07-25
申请号：US18600097
申请日：2024-03-08
发明人： Katrina L. Jackson , Christopher G. Nasveschuk , Rhamy Zeid , Ning Yin , Gesine Kerstin Veits , Moses Moustakim , Jeremy L. Yap , Minsheng He , Robert T. Yu , Matthew J. Schnaderbeck , Kathleen Neville , Siyi Jiang , Meiqi Li , Qianwei Liu , Manjie Zheng , Jia Li , Liwei Zhang
IPC分类号： A61K31/496 , A61P35/00
CPC分类号： A61K31/496 , A61P35/00
摘要： Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
-
公开(公告)号：US20240051953A1
公开(公告)日：2024-02-15
申请号：US17965569
申请日：2022-10-13
发明人： Christopher G. Nasveschuk , Rhamy Zeid , Ning Yin , Katrina L. Jackson , Gesine Kerstin Veits , Moses Moustakim , Jeremy L. Yap
IPC分类号： C07D471/04 , C07D401/14 , A61P35/00
CPC分类号： C07D471/04 , A61P35/00 , C07D401/14
摘要： BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
-
公开(公告)号：US11691972B2
公开(公告)日：2023-07-04
申请号：US17541035
申请日：2021-12-02
发明人： Christopher G. Nasveschuk , Rhamy Zeid , Ning Yin , Katrina L. Jackson , Gesine Kerstin Veits , Moses Moustakim , Jeremy L. Yap
IPC分类号： C07D471/04 , C07D401/14 , A61P35/00
CPC分类号： C07D471/04 , A61P35/00 , C07D401/14
摘要： A BRD9 protein degrading compound of structure
or a pharmaceutically acceptable salt thereof is provided for the treatment of a disorder mediated by BRD9, including but not limited to abnormal cellular proliferation including cancer.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.036 秒)
